证券代码：301033 证券简称：迈普医学 上市地点：深圳证券交易所 广州迈普再生医学科技股份有限公司 发行股份及支付现金购买资产并募集配套资金 暨关联交易预案（修订稿） 项目 交易对方 购买资产交易对方 广州泽新医疗科技有限公司等 10 名交易对方 募集配套资金认购方 广州易见医疗投资有限公司 二〇二五年八月 上市公司声明 本公司、控股股东、全体董事、监事、高级管理人员保证本预案内容及其摘要内 容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。如因提供的信息、 出具的说明及确认存在虚假记载、误导性陈述或重大遗漏，给投资者造成损失的，将 依法承担相应法律责任。 本公司、控股股东、全体董事、监事、高级管理人员承诺：如本人在本次交易所 披露或提供的信息涉嫌虚假记载、误导性陈述或者重大遗漏，被司法机关立案侦查或 者被中国证监会立案调查的，在形成调查结论以前，不转让在上市公司拥有权益的股 份（如有，下同），并于收到立案稽查通知的两个交易日内将暂停转让的书面申请和 股票账户提交上市公司董事会，由董事会代其向证券交易所和证券登记结算机构申请 锁定；未在两个交易日内提交锁定申请的，授权董事会核实后直接向证券交易所 ...

Group 1 - The company, Guangzhou Maipu Regenerative Medicine Technology Co., Ltd., plans to acquire 100% equity of Yijie Medical through issuing shares and cash payment, along with raising supporting funds [7][14] - The target company, Yijie Medical, specializes in the research, production, and sales of neuro-interventional medical devices, which aligns with the company's focus on high-performance implantable medical devices [14][26] - The transaction aims to expand the company's product portfolio and enhance its market presence in the neuro-interventional field, which is experiencing significant growth due to increasing demand for innovative treatment options for cerebrovascular diseases [14][26] Group 2 - The company has established a strong distribution network with nearly 1,000 domestic and international distributors, covering around 2,000 hospitals in China and over 100 countries globally [14] - The neurovascular intervention medical consumables market in China is projected to grow from 3.2 billion RMB in 2017 to 43.2 billion RMB by 2028, with a compound annual growth rate of 36.5% [26] - The company has received multiple medical device registrations and certifications, indicating its commitment to quality and compliance in the medical device sector [25][26] Group 3 - The transaction is subject to regulatory approvals and the completion of auditing and evaluation processes, which are still ongoing as of the date of the announcement [2][19] - The company has committed to strict information disclosure obligations and will provide updates on the transaction's progress to ensure transparency for investors [18] - The controlling shareholder and management have pledged not to reduce their holdings during the transaction process, reinforcing their commitment to the company's stability [17]

Core Viewpoint - Maipu Medical announced a restructuring plan to acquire 100% of Yijie Medical, which is expected to expand its product offerings in the neurosurgery field, despite concerns over potential financial impacts due to Yijie Medical's current losses [2][3]. Group 1: Company Overview - Maipu Medical is the only company in China's neurosurgery field that offers a comprehensive range of implantable medical devices, including artificial dura mater patches and absorbable hemostatic agents [2]. - Yijie Medical specializes in the research, design, and sales of vascular interventional medical devices for neurology, with products such as neurointerventional catheters and balloon dilation catheters [2]. Group 2: Financial Performance - In 2024, Maipu Medical reported a net profit of 78.85 million yuan, showing a growth trend from 2022 to 2024 [3]. - Yijie Medical is projected to incur net losses of 29.51 million yuan in 2023 and 26.16 million yuan in 2024, raising concerns about the impact of the acquisition on Maipu Medical's financial performance [3]. Group 3: Market and Competitive Landscape - The acquisition is seen as a strategic move to enhance Maipu Medical's product categories by integrating biocomposite material technology into the interventional field [2]. - There are concerns regarding market competition, as existing products in the neurointerventional medical device sector maintain high market shares, and potential new products could disrupt the market [3].